The new delivery vehicle, known as FL0445-LNP, belongs to a class of microscopic particles that function somewhat like molecular containers. Lipid nanoparticles are assembled from fat-like molecules that form a protective structure around nucleic acids. Their outer surfaces are compatible with the watery environment of the body, while their lipid composition helps them interact with cell membranes. After being taken up by cells, the particles are designed to break down and release their cargo. This process allows the delivered mRNA or circular RNA to reach the cellular machinery responsible for translating genetic instructions into proteins.

The need for such protection arises from the inherent instability of linear mRNA. A conventional messenger RNA molecule has defined ends, including a cap structure that helps ribosomes recognize it and a tail that contributes to stability and translation. These same terminal regions, however, can also become targets for cellular enzymes that degrade RNA. Once the molecule is destroyed, protein production stops. This limited lifetime is useful for some applications, including transient vaccination, but it can be a disadvantage when a therapeutic protein needs to be produced over a longer period.

Circular RNA, or cirRNA, offers a different molecular architecture. Instead of having two exposed ends, the RNA strand is joined into a continuous loop. This configuration removes the terminal points that many degradation enzymes attack, potentially allowing the molecule to remain active in cells for longer periods. Because circular RNA lacks a natural stop point, ribosomes may repeatedly move around the loop and generate multiple copies of the encoded protein. Yet the structure also introduces a challenge: circular RNA does not naturally possess the cap-and-tail arrangement that makes linear mRNA highly efficient at initiating translation.

To address this limitation, Hiroshi Abe, Seigo Kimura, and colleagues at Nagoya University’s Integrated Research Consortium on Chemical Sciences and Department of Chemistry developed a capped circular RNA construct called Cap-cirRNA. The design retains the closed-loop structure associated with increased resistance to degradation while adding a cap-related feature intended to improve the initiation of protein synthesis. The researchers describe the approach as an effort to combine the durability of circular RNA with the strong translation performance of conventional mRNA. In principle, this could allow cells to produce a therapeutic protein efficiently without requiring repeated administration of unstable RNA molecules.

The team paired Cap-cirRNA with FL0445-LNP, a nanoparticle obtained from researchers at the Bioscience & Engineering Laboratories of FUJIFILM Corporation. A notable feature of the particle is the branched biodegradable chains within its ionizable lipid component. Conventional lipid nanoparticles often rely on lipids with more linear structures. By introducing branching, the researchers sought to create a more flexible internal environment capable of accommodating nucleic acids with different sizes, weights, and molecular shapes. That flexibility may be particularly important for circular RNA, whose geometry and physical properties differ from those of linear mRNA.

In comparative experiments, FL0445-LNP increased mRNA activity by approximately tenfold relative to conventional lipid nanoparticle formulations, while producing a negligible inflammatory response under the reported conditions. The finding is significant because inflammation remains an important consideration in RNA medicine. Lipid nanoparticles must be sufficiently active to deliver their cargo, but excessive immune stimulation can limit dosing, reduce tolerability, or complicate repeated treatment. A biodegradable and adaptable particle that combines efficient delivery with a restrained inflammatory profile could therefore be useful across several classes of nucleic-acid therapies.

For an initial therapeutic test, the researchers selected GLP-1, a peptide hormone that helps regulate blood glucose and appetite. Current GLP-1 medicines, including drugs used in obesity treatment, generally deliver the peptide or a peptide analogue directly through injection. An RNA-based strategy takes a different route: rather than supplying the finished protein, it provides cells with the genetic instructions needed to manufacture it. If those instructions remain active for an extended period, the approach could potentially reduce the frequency of injections. In the mouse experiments, FL0445-LNP successfully delivered both linear mRNA and Cap-cirRNA encoding GLP-1 and produced measurable biological activity.

Cap-cirRNA showed greater functional activity than the corresponding linear mRNA in the animal studies, although the researchers emphasize that the system requires further optimization before its therapeutic potential can be assessed in humans. Important questions remain concerning dose, tissue distribution, duration of protein production, immune responses after repeated administration, and the control of circular RNA activity. The amount of protein produced must also be carefully regulated, since prolonged or excessive expression could create safety risks depending on the therapeutic target. Nevertheless, the results provide evidence that a branched ionizable lipid nanoparticle can serve as a common delivery platform for chemically and structurally distinct RNA cargos.

The researchers envision applications extending beyond GLP-1 therapy. The platform could support next-generation vaccines in which durable protein production improves immune training, as well as cancer vaccines designed to present tumor-associated antigens to the immune system. It may also be relevant to genome-editing technologies, which require the temporary delivery of messenger RNA and editing components into cells. In genetic disorders caused by missing or defective proteins, the same strategy might provide instructions for producing a functional replacement protein. By pairing a versatile nanoparticle with RNA molecules engineered for either rapid or prolonged activity, the work points toward a broader toolkit for protein replacement, vaccination, and other forms of precision medicine.

Subject of Research: Cells

Article Title: A Branched Ionizable Lipid Nanoparticle Platform for Versatile In Vivo Delivery of Nucleic Acids: Validation from mRNA to Capped Circular RNA

News Publication Date: 19-Aug-2026

Web References: Nagoya University Integrated Research Consortium on Chemical Sciences: https://irccs.nagoya-u.ac.jp/ ; Nagoya University Department of Chemistry: https://www.chem.nagoya-u.ac.jp/en/

References: Cell Biomaterials, “A Branched Ionizable Lipid Nanoparticle Platform for Versatile In Vivo Delivery of Nucleic Acids: Validation from mRNA to Capped Circular RNA,” published 19-Aug-2026.

Image Credits: Sumeet Kulkarni, Nagoya University

Keywords: mRNA, circular RNA, Cap-cirRNA, lipid nanoparticles, FL0445-LNP, nucleic-acid delivery, GLP-1, RNA therapeutics, obesity treatment, cancer vaccines, genome editing, Nagoya University

Gene therapy hinges crucially on the ability to transport nucleic acids—such as messenger RNA (mRNA) or CRISPR-Cas9 components—into specific cells while evading immune detection and off-target effects. Conventional LNPs, although successful in systemic delivery, often suffer from a lack of tissue specificity and limited efficiency when it comes to targeting lung tissue. This new generation of LuT lipids, architected with a tripod-like structural motif, ingeniously exploits the unique microenvironment of pulmonary cells, enabling precise docking and uptake. The trifurcated design enhances the particle’s stability and facilitates receptor-mediated endocytosis, dramatically improving delivery outcomes.

The research team embarked on an extensive structure-activity relationship (SAR) study to optimize the arrangement and chemical composition of LuT lipids. By synthesizing diverse lipid variants with distinct head groups, linker segments, and hydrophobic tails, the scientists meticulously tuned the physicochemical properties of the LNPs. Among the pivotal findings was the realization that the tripod configuration endowed the particles with an optimal balance of fluidity and rigidity. This balance is crucial for traversing the pulmonary extracellular matrix and cellular membranes, ensuring both protection of the cargo and its efficient release within target cells.

Beyond the particle’s structural novelty, the LuT lipids integrate molecular features that inherently favor lung microenvironment compatibility. These features include tailored hydrophobicity matching the surfactant-laden alveolar space and chemical groups that selectively engage with lung-enriched receptors. As a result, the LNPs exhibit markedly reduced accumulation in off-target organs such as the liver and spleen, a common pitfall in systemic lipid-based delivery systems. This refinement minimizes systemic toxicity, a critical consideration in clinical translation.

Perhaps most striking is the demonstrable efficacy of LuT LNPs in vivo. Animal models revealed that these nanoparticles achieved significantly higher gene expression levels in lung tissue post-administration compared to benchmark LNP formulations. The enhanced delivery facilitated successful gene editing via CRISPR-Cas9, correcting disease-causing mutations with remarkable precision and minimal immune activation. These outcomes were validated through a battery of assays including quantitative PCR, histological analysis, and immunogenicity profiling, underscoring both the potency and safety of the platform.

The implications of this technology extend far beyond lung disease. By establishing a blueprint for tissue-specific LNP design, this work opens avenues for customized gene therapies targeting other organs with high precision. The modularity of the tripod lipid scaffold allows for chemical modifications tailored to diverse biological contexts, promising a new era of personalized nanomedicine. Such adaptability could accelerate the development pipeline for genetic interventions across a spectrum of pathologies.

Underlying these achievements is a sophisticated understanding of lipid chemistry and nanostructure dynamics, which the researchers harnessed to engineer a multifaceted delivery vehicle. The tripod geometry optimizes lipid packing parameters, facilitating spontaneous self-assembly into nanoparticles of defined size and surface charge. This homogeneity is critical for predictable pharmacokinetics and biodistribution, factors often hampering clinical applicability of nanocarriers.

The team further demonstrated that the LuT LNPs can be loaded efficiently with various nucleic acid cargos, ranging from short interfering RNA (siRNA) to large mRNA molecules. This versatility underscores the platform’s potential as a universal delivery system, adaptable to diverse therapeutic modalities, including protein replacement therapies and vaccination strategies. Notably, the LNPs maintained their structural integrity and functional performance after systemic administration, overcoming common degradation challenges faced in the bloodstream.

Safety profiling of the LuT lipids revealed an excellent biocompatibility profile. Treated animals showed no signs of acute or chronic inflammation, and hematological parameters remained within normal ranges. These findings assuage concerns about lipid-induced cytotoxicity and inflammatory responses, which have historically limited repeated dosing regimens in gene therapy protocols. This favorable safety window enhances the clinical appeal of the platform, signaling readiness for further preclinical and potentially early-phase human trials.

This breakthrough also intersects with advances in CRISPR genome editing technologies, amplifying their therapeutic potential. The precise delivery enabled by LuT LNPs reduces off-target edits by confining CRISPR components to intended cells. Such spatial control mitigates risks of genomic instability and unintended mutations, strengthening the ethical and regulatory case for clinical deployment. Consequently, the convergence of chemistry-driven nanoparticle design and gene editing heralds a new paradigm in molecular medicine.

Importantly, this work arrives at a time when respiratory diseases remain a leading cause of global morbidity and mortality. The ongoing COVID-19 pandemic magnified the need for efficacious pulmonary delivery strategies, not only for vaccines but also for antiviral gene therapies. The LuT LNP platform, with its lung-selective tropism and delivery efficiency, could be adapted for emergency responsiveness against respiratory pathogens, thereby broadening its societal impact.

While the current studies provide compelling proof-of-concept, the authors acknowledge the imperative for comprehensive pharmacodynamic analyses and scaling challenges. Manufacturing robustness, reproducibility, and cost-effectiveness of LuT lipid synthesis are key parameters to address before clinical translation. Moreover, long-term biodistribution and immunological ramifications require further exploration to ensure sustained safety over repeated administrations.

In conclusion, the advent of tripod-like lung-targeting lipids marks a transformative milestone in targeted gene delivery systems. By marrying innovative molecular design with functional performance in challenging tissue environments, this technology redefines possibilities for treating genetic and acquired lung disorders. The modular platform promises to accelerate the journey from bench to bedside, delivering tangible benefits in precision therapeutics. As the field eagerly anticipates expanded validation and clinical evaluation, the future of lung-directed gene editing looks more promising than ever.

Subject of Research: Lung-targeted lipid nanoparticles for efficient gene delivery and genome editing.

Article Title: ‘Tripod-like’ lung-targeting (LuT) lipids for highly efficient and selective LNPs for gene delivery and editing.

Article References:
Tian, Z., Wang, X., Chatterjee, S. et al. ‘Tripod-like’ lung-targeting (LuT) lipids for highly efficient and selective LNPs for gene delivery and editing. Nat. Biomed. Eng (2026). https://doi.org/10.1038/s41551-026-01615-9

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41551-026-01615-9